InvestorsObserver is giving Cerevel Therapeutics Holdings Inc (CERE) an Analyst Rating Rank of 76, meaning CERE is ranked higher by analysts than 76% of stocks. The average price target for CERE is $21.5 and analyst’s rate the stock as a Hold
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Cerevel Therapeutics Holdings Inc Stock Today?
Cerevel Therapeutics Holdings Inc (CERE) stock has fallen -1.31% while the S&P 500 has risen 1.41% as of 10:42 AM on Thursday, May 13. CERE is lower by -$0.18 from the previous closing price of $13.72 on volume of 21,910 shares. Over the past year the S&P 500 is higher by 26.93% while CERE has risen 13.78%. CERE lost -$2.01 per share the over the last 12 months.
Click Here to get the full report on Cerevel Therapeutics Holdings Inc (CERE) Stock.
